“Companies in a pandemic should be applauded for testing lower doses, which will extend supply,” CP3 Director Dr. Walid Gellad told Endpoints News' Zachary Brennan regarding Regeneron's monoclonal antibody cocktail for Covid-19. Regeneron is seeking an EUA for a lower dose of the treatment, which has shown to lower risk of hospitalizations and death.